Logo Logo
Exportieren als [RSS feed] RSS 1.0 [RSS2 feed] RSS 2.0
Gruppiert nach: Dokumententyp | Veröffentlichungsdatum
Springe zu: 2024 | 2022 | 2021 | 2020 | 2019
Anzahl der Publikationen: 6

2024

Boukovala, Myrto; Modest, Dominik Paul; Ricard, Ingrid; Fischer von Weikersthal, Ludwig; Decker, Thomas; Vehling-Kaiser, Ursula; Uhlig, Jens; Schenk, Michael; Freiberg-Richter, Jens; Peuser, Bettina; Denzlinger, Claudio; Peveling Genannt Reddemann, C.; Graeven, Ullrich ORCID logoORCID: https://orcid.org/0000-0001-6082-7710; Schuch, Gunter ORCID logoORCID: https://orcid.org/0000-0001-7503-457X; Schwaner, Ingo ORCID logoORCID: https://orcid.org/0000-0001-8865-7282; Heinrich, Kathrin ORCID logoORCID: https://orcid.org/0000-0003-3580-2313; Neumann, Jens; Jung, Andreas; Held, Swantje ORCID logoORCID: https://orcid.org/0000-0002-1344-9056; Stintzing, Sebastian ORCID logoORCID: https://orcid.org/0000-0002-3297-5801; Heinemann, Volker ORCID logoORCID: https://orcid.org/0000-0002-1349-3321 und Michl, Marlies ORCID logoORCID: https://orcid.org/0000-0002-4198-3627 (2024): Evaluation of the inflammation-based modified Glasgow Prognostic Score (mGPS) as a prognostic and predictive biomarker in patients with metastatic colorectal cancer receiving first-line chemotherapy: a post hoc analysis of the randomized phase III XELAVIRI trial (AIO KRK0110). In: ESMO Open, Bd. 9, Nr. 5, 103374 [PDF, 725kB]

2022

Fischer, Laura E. ORCID logoORCID: https://orcid.org/0000-0001-8752-5827; Stintzing, Sebastian; Weikersthal, Ludwig Fischer von; Modest, Dominik P.; Decker, Thomas; Kiani, Alexander ORCID logoORCID: https://orcid.org/0000-0002-2494-4087; Kaiser, Florian; Al-Batran, Salah-Eddin; Heintges, Tobias; Lerchenmüller, Christian; Kahl, Christoph; Seipelt, Gernot; Kullmann, Frank; Stauch, Martina; Scheithauer, Werner; Giessen-Jung, Clemens; Uhlig, Jens; Peuser, Bettina; Denzlinger, Claudio; Stahler, Arndt; Weiss, Lena; Heinrich, Kathrin; Held, Swantje; Jung, Andreas; Kirchner, Thomas und Heinemann, Volker (2022): Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3. In: British Journal of Cancer, Bd. 127, Nr. 5: S. 836-843 [PDF, 788kB]

Kurreck, Annika; Heinemann, Volker; Fischer von Weikersthal, Ludwig; Decker, Thomas; Kaiser, Florian; Uhlig, Jens; Schenk, Michael; Freiberg-Richter, Jens; Peuser, Bettina; Denzlinger, Claudio; Graeven, Ullrich; Heinrich, Kathrin; Held, Swantje; Stahler, Arndt; Alig, Annabel Helga Sophie; Jelas, Ivan; Einem, Jobst C. von; Stintzing, Sebastian; Giessen-Jung, Clemens und Modest, Dominik P. (2022): Response and Disease Dynamics in Untreated Metastatic Colorectal Cancer With Bevacizumab-Based Sequential vs. Combination Chemotherapy-Analysis of the Phase 3 XELAVIRI Trial. In: Frontiers in Oncology, Bd. 12, 751453

2021

Heinrich, Kathrin; Modest, Dominik P.; Ricard, Ingrid; Fischer von Weikersthal, Ludwig; Decker, Thomas; Kaiser, Florian; Graeven, Ullrich; Uhlig, Jens; Schenk, Michael; Freiberg-Richter, Jens; Peuser, Bettina; Denzlinger, Claudio; Giessen-Jung, Clemens; Stahler, Arndt; Michl, Marlies; Held, Swantje; Jung, Andreas; Kirchner, Thomas; Stintzing, Sebastian und Heinemann, Volker (2021): Gender-dependent survival benefit from first-line irinotecan in metastatic colorectal cancer. Subgroup analysis of a phase III trial (XELAVIRI-study, AIO-KRK-0110). In: European Journal of Cancer, Bd. 147: S. 128-139

2020

Kurreck, Annika; Heinemann, Volker; Fischer von Weikersthal, Ludwig; Decker, Thomas; Kaiser, Florian; Uhlig, Jens; Schenk, Michael; Freiberg-Richter, Jens; Peuser, Bettina; Denzlinger, Claudio; Graeven, Ullrich; Schwaner, Ingo; Stahler, Arndt; Heinrich, Kathrin; Jung, Andreas; Held, Swantje; von Einem, Jobst C.; Stintzing, Sebastian; Giessen-Jung, Clemens und Modest, Dominik P. (2020): Impact of age on efficacy and early mortality of initial sequential treatment versus upfront combination chemotherapy in patients with metastatic colorectal cancer: a subgroup analysis of a phase III trial (AIO KRK0110, XELAVIRI study). In: European Journal of Cancer, Bd. 137: S. 81-92

2019

Modest, Dominik Paul; Fischer von Weikersthal, Ludwig; Decker, Thomas; Vehling-Kaiser, Ursula; Uhlig, Jens; Schenk, Michael; Freiberg-Richter, Jens; Peuser, Bettina; Denzlinger, Claudio; Reddemann, Christina Peveling Genannt; Graeven, Ullrich; Schuch, Gunter; Schwaner, Ingo; Stahler, Arndt; Jung, Andreas; Kirchner, Thomas; Held, Swantje; Stintzing, Sebastian; Giessen-Jung, Clemens und Heinemann, Volker (2019): Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled StudyXELAVIRI (AIO KRK0110). In: Journal of Clinical Oncology, Bd. 37, Nr. 1

Diese Liste wurde am Sat Dec 21 22:06:07 2024 CET erstellt.